430 related articles for article (PubMed ID: 21192925)
1. Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53.
Sung KS; Lee YA; Kim ET; Lee SR; Ahn JH; Choi CY
Exp Cell Res; 2011 Apr; 317(7):1060-70. PubMed ID: 21192925
[TBL] [Abstract][Full Text] [Related]
2. PML tumor suppressor is regulated by HIPK2-mediated phosphorylation in response to DNA damage.
Gresko E; Ritterhoff S; Sevilla-Perez J; Roscic A; Fröbius K; Kotevic I; Vichalkovski A; Hess D; Hemmings BA; Schmitz ML
Oncogene; 2009 Feb; 28(5):698-708. PubMed ID: 19015637
[TBL] [Abstract][Full Text] [Related]
3. PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains.
Möller A; Sirma H; Hofmann TG; Rueffer S; Klimczak E; Dröge W; Will H; Schmitz ML
Cancer Res; 2003 Aug; 63(15):4310-4. PubMed ID: 12907596
[TBL] [Abstract][Full Text] [Related]
4. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2.
Hofmann TG; Möller A; Sirma H; Zentgraf H; Taya Y; Dröge W; Will H; Schmitz ML
Nat Cell Biol; 2002 Jan; 4(1):1-10. PubMed ID: 11740489
[TBL] [Abstract][Full Text] [Related]
5. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis.
D'Orazi G; Cecchinelli B; Bruno T; Manni I; Higashimoto Y; Saito S; Gostissa M; Coen S; Marchetti A; Del Sal G; Piaggio G; Fanciulli M; Appella E; Soddu S
Nat Cell Biol; 2002 Jan; 4(1):11-9. PubMed ID: 11780126
[TBL] [Abstract][Full Text] [Related]
6. Role of nuclear bodies in apoptosis signalling.
Krieghoff-Henning E; Hofmann TG
Biochim Biophys Acta; 2008 Nov; 1783(11):2185-94. PubMed ID: 18680765
[TBL] [Abstract][Full Text] [Related]
7. Control of nuclear HIPK2 localization and function by a SUMO interaction motif.
de la Vega L; Fröbius K; Moreno R; Calzado MA; Geng H; Schmitz ML
Biochim Biophys Acta; 2011 Feb; 1813(2):283-97. PubMed ID: 21145359
[TBL] [Abstract][Full Text] [Related]
8. Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.
Maroui MA; Kheddache-Atmane S; El Asmi F; Dianoux L; Aubry M; Chelbi-Alix MK
PLoS One; 2012; 7(9):e44949. PubMed ID: 23028697
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of component exchange at PML nuclear bodies.
Weidtkamp-Peters S; Lenser T; Negorev D; Gerstner N; Hofmann TG; Schwanitz G; Hoischen C; Maul G; Dittrich P; Hemmerich P
J Cell Sci; 2008 Aug; 121(Pt 16):2731-43. PubMed ID: 18664490
[TBL] [Abstract][Full Text] [Related]
10. PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence.
Ivanschitz L; Takahashi Y; Jollivet F; Ayrault O; Le Bras M; de Thé H
Proc Natl Acad Sci U S A; 2015 Nov; 112(46):14278-83. PubMed ID: 26578773
[TBL] [Abstract][Full Text] [Related]
11. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitor, methyl 2,5-dihydromethylcinnimate, induces PML nuclear body formation and apoptosis in tumor cells.
Komura N; Asakawa M; Umezawa K; Segawa K
Exp Cell Res; 2007 Aug; 313(13):2753-65. PubMed ID: 17585903
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells.
Herzer K; Weyer S; Krammer PH; Galle PR; Hofmann TG
Cancer Res; 2005 Dec; 65(23):10830-7. PubMed ID: 16322229
[TBL] [Abstract][Full Text] [Related]
14. Covalent modification of human homeodomain interacting protein kinase 2 by SUMO-1 at lysine 25 affects its stability.
Gresko E; Möller A; Roscic A; Schmitz ML
Biochem Biophys Res Commun; 2005 Apr; 329(4):1293-9. PubMed ID: 15766567
[TBL] [Abstract][Full Text] [Related]
15. The homeodomain-interacting kinase PKM (HIPK-2) modifies ND10 through both its kinase domain and a SUMO-1 interaction motif and alters the posttranslational modification of PML.
Engelhardt OG; Boutell C; Orr A; Ullrich E; Haller O; Everett RD
Exp Cell Res; 2003 Feb; 283(1):36-50. PubMed ID: 12565818
[TBL] [Abstract][Full Text] [Related]
16. Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR.
Winter M; Sombroek D; Dauth I; Moehlenbrink J; Scheuermann K; Crone J; Hofmann TG
Nat Cell Biol; 2008 Jul; 10(7):812-24. PubMed ID: 18536714
[TBL] [Abstract][Full Text] [Related]
17. ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
Kunapuli P; Kasyapa CS; Chin SF; Caldas C; Cowell JK
Exp Cell Res; 2006 Nov; 312(19):3739-51. PubMed ID: 17027752
[TBL] [Abstract][Full Text] [Related]
18. AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation.
Li Q; He Y; Wei L; Wu X; Wu D; Lin S; Wang Z; Ye Z; Lin SC
Oncogene; 2011 Mar; 30(10):1194-204. PubMed ID: 21057547
[TBL] [Abstract][Full Text] [Related]
19. Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
Percherancier Y; Germain-Desprez D; Galisson F; Mascle XH; Dianoux L; Estephan P; Chelbi-Alix MK; Aubry M
J Biol Chem; 2009 Jun; 284(24):16595-16608. PubMed ID: 19380586
[TBL] [Abstract][Full Text] [Related]
20. Zyxin is a critical regulator of the apoptotic HIPK2-p53 signaling axis.
Crone J; Glas C; Schultheiss K; Moehlenbrink J; Krieghoff-Henning E; Hofmann TG
Cancer Res; 2011 Mar; 71(6):2350-9. PubMed ID: 21248071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
